Abstract
Purpose: Until now molecular biologic techniques have not been easily used in daily clinical practice to stratify patients for therapeutic purposes. Therefore, we have investigated the prognostic relevance of the immunohistochemical (IHC) germinal center B-cell (GCB) versus non-GCB diffuse large B-cell lymphoma (DLBCL) subtypes. Patient; and Methods: We have analyzed tumor samples from patients treated in 2 prospective multicenter phase III trials, ie HOVON 25 (patients >= 65 years, n = 153) and HOVON 26 (patients
| Original language | English |
|---|---|
| Pages (from-to) | 23-32 |
| Number of pages | 10 |
| Journal | Clinical lymphoma myeloma & leukemia |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb-2011 |
Keywords
- DLBCL
- Germinal center B-cell
- Immunohistochemistry
- NON-HODGKINS-LYMPHOMA
- CHEMOTHERAPY PLUS RITUXIMAB
- RANDOMIZED CONTROLLED-TRIAL
- GERMINAL CENTER PHENOTYPE
- ELDERLY-PATIENTS
- TISSUE MICROARRAY
- RISK STRATIFICATION
- PROTEIN EXPRESSION
- DISTINCT SUBGROUPS
- CD10 EXPRESSION
Fingerprint
Dive into the research topics of 'Prognostic Relevance of Immunohistochemical Subclassification of Diffuse Large B-Cell Lymphoma in Two Prospective Phase III Clinical Trials'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver